Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Ixekizumab in Psoriasis and Psoriatic Arthritis in India
NCT05855967Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ixekizumab in plaque psoriasis, psoriatic arthritis (PsA), sponsored by Eli Lilly and Company. Started Jun 2023; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT05855967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05855967.